The filing is a routine preclinical update with no new clinical or commercial catalysts. Monitor for Phase 1 initiation or partnership announcements as the next potential value drivers. Historical stock reaction to similar MIRA news has been negative, suggesting limited near-term upside from this data alone.
Price Chart
Executive Summary
MIRA Pharmaceuticals announced positive preclinical results for lead oral formulation of MIRA-55, demonstrating favorable oral bioavailability and brain/liver distribution. This is a routine pipeline update with no financial data or clinical milestones; the stock has historically not reacted positively to similar disclosures.
Key Facts
- Selected lead oral formulation of MIRA-55 with favorable oral bioavailability and sustained systemic exposure
- Preclinical study showed reproducible distribution into brain and liver tissue following oral administration
- MIRA-55 previously normalized pain and outperformed injected morphine in a validated inflammatory pain model
- DEA determined MIRA-55 is not a controlled substance
- MIRA-55 is a preclinical-stage candidate; no clinical data or regulatory milestones announced
Financial Impact
No financial figures disclosed; preclinical data only
Risk Factors
- Preclinical-to-clinical translation risk; animal data may not predict human results
- MIRA-55 is still in preclinical stage, requiring significant additional studies and regulatory approvals
- Low market cap ($38M) and historical negative stock drift post-filings indicate fragile investor sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032777 |
| Exhibit: ex99-1.htm | 0001493152-26-032777 |
| Document: 0001493152-26-032777-index-headers.html | 0001493152-26-032777 |
| Document: 0001493152-26-032777-index.html | 0001493152-26-032777 |
| Document: 0001493152-26-032777.txt | 0001493152-26-032777 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5600 (−10.97%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5600 (−10.96%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5600 (−26.25%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5600 (−26.25%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5600 (−34.88%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5600 (−17.43%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5600 (−39.43%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5600 (−41.36%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5600 (−42.75%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5600 (−42.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers